Division of Endocrinology, Diabetes & Metabolism, University of Florida, Gainesville, FL.
Malcom Randall Veterans Administration Medical Center, Gainesville, FL.
Diabetes Care. 2018 Jan;41(1):187-192. doi: 10.2337/dc17-1349. Epub 2017 Nov 13.
There has been a widespread misconception among physicians that African Americans are protected from developing nonalcoholic steatohepatitis (NASH). However, a formal histologic and metabolic comparison against well-matched Caucasians has never been performed.
Sixty-seven African American patients were matched 2:1 to Caucasians ( = 134) for age, sex, BMI, hemoglobin A, and prevalence of type 2 diabetes mellitus (T2DM). Screening for NASH included measurement of intrahepatic triglyceride content by proton MRS (H-MRS), followed by a liver biopsy if patients had hepatic steatosis. Insulin resistance was estimated during an oral glucose tolerance test using the Matsuda Index.
Compared with Caucasians, African American patients had a lower intrahepatic triglyceride content (mean ± SD 6.1 ± 6.8% vs. 9.4 ± 7.5%, = 0.007) and the presence of nonalcoholic fatty liver disease (NAFLD) was less common (25.0% vs. 51.9%, = 0.003). However, prevalence of NASH was not different between ethnicities in patients with NAFLD (57.1% vs. 73.3%, = 0.12). Moreover, they showed similar severity in each of the individual histologic parameters (inflammation, ballooning, and fibrosis). Among patients with NAFLD, insulin resistance was similar between both ethnic groups (Matsuda Index: 3.3 ± 1.8 vs. 3.1 ± 1.9, = 0.61; adipose tissue insulin resistance [Adipo-IR] index: 5.7 ± 4.6 vs. 6.4 ± 4.7 mmol/L ⋅ µU/mL, = 0.53) but appeared to be worse in African American versus Caucasian patients without NAFLD (Matsuda Index: 4.9 ± 3.6 vs. 7.0 ± 4.9, = 0.11; Adipo-IR: 3.9 ± 2.8 vs. 2.7 ± 2.3 mmol/L ⋅ µU/mL, = 0.06). African American patients also had lower plasma triglycerides and higher HDL cholesterol, independent of the severity of intrahepatic triglyceride.
Although African Americans have lower intrahepatic triglyceride accumulation, once NAFLD develops, NASH occurs as frequently, and as severe, as in Caucasian patients. Therefore, African Americans with NAFLD should be screened for NASH with the same degree of clinical resolve as in Caucasian patients.
医生中普遍存在一种误解,认为非裔美国人不会患上非酒精性脂肪性肝炎(NASH)。然而,针对非裔美国人和与之相匹配的白人进行正式的组织学和代谢比较从未进行过。
将 67 名非裔美国患者按年龄、性别、BMI、血红蛋白 A 和 2 型糖尿病(T2DM)患病率与白人进行 2:1 配对(=134)。通过质子磁共振波谱(H-MRS)测量肝内甘油三酯含量,如果患者存在肝脂肪变性,则进行肝活检。在口服葡萄糖耐量试验期间,使用 Matsuda 指数估计胰岛素抵抗。
与白人相比,非裔美国患者的肝内甘油三酯含量较低(平均值±标准差 6.1±6.8%比 9.4±7.5%,=0.007),非酒精性脂肪性肝病(NAFLD)的患病率较低(25.0%比 51.9%,=0.003)。然而,在患有 NAFLD 的患者中,两种族之间 NASH 的患病率没有差异(57.1%比 73.3%,=0.12)。此外,他们在每个组织学参数(炎症、气球样变和纤维化)中表现出相似的严重程度。在患有 NAFLD 的患者中,两组之间的胰岛素抵抗相似(Matsuda 指数:3.3±1.8 比 3.1±1.9,=0.61;脂肪组织胰岛素抵抗[Adipo-IR]指数:5.7±4.6 比 6.4±4.7mmol/L ⋅ µU/mL,=0.53),但在非 NAFLD 的非裔美国患者中似乎更差(Matsuda 指数:4.9±3.6 比 7.0±4.9,=0.11;Adipo-IR:3.9±2.8 比 2.7±2.3mmol/L ⋅ µU/mL,=0.06)。非裔美国患者的血浆甘油三酯水平较低,HDL 胆固醇水平较高,与肝内甘油三酯的严重程度无关。
尽管非裔美国人肝内甘油三酯的积累较低,但一旦发生 NAFLD,NASH 的发生频率和严重程度与白人患者相同。因此,患有 NAFLD 的非裔美国人应与白人患者一样,以同样的临床决心筛查 NASH。